Massimo Falconi
Vita-Salute San Raffaele University
SurgeryPancreasDiabetes mellitusGeneral surgeryMedicine
What is this?
Publications 696
#1S. Lof (University of Southampton)H-Index: 1
#1Sanne LofH-Index: 2
Last. M. Abu HilalH-Index: 22
view all 19 authors...
Background: Several studies have suggested a survival benefit of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data concerning NAT for PDAC located in pancreatic body or tail are lacking. Methods: Post hoc analysis of an international multicenter retrospective cohort of distal pancreatectomy for PDAC in 34 centers from 11 countries (2007–2015). Patients who underwent resection after NAT were matched (1:1 ratio), using propensity scores based on bas...
#1Florian PrimavesiH-Index: 7
#2Valentina AndreasiH-Index: 3
Last. Uwe FröschlH-Index: 3
view all 28 authors...
Background: Oncological survival after resection of pancreatic neuroendocrine neoplasms (panNEN) is highly variable depending on various factors. Risk stratification with preoperatively available parameters could guide decision-making in multidisciplinary treatment concepts. C-reactive Protein (CRP) is linked to inferior survival in several malignancies. This study assesses CRP within a novel risk score predicting histology and outcome after surgery for sporadic non-functional panNENs. Methods: ...
#1G. Rossi (UniSR: Vita-Salute San Raffaele University)H-Index: 4
#2Maria Chiara Petrone (UniSR: Vita-Salute San Raffaele University)H-Index: 16
Last. Paolo Giorgio Arcidiacono (UniSR: Vita-Salute San Raffaele University)H-Index: 29
view all 7 authors...
#1Livia Archibugi (UniSR: Vita-Salute San Raffaele University)H-Index: 8
#2S.G.G. Testoni (UniSR: Vita-Salute San Raffaele University)H-Index: 1
Last. P.G. Arcidiacono (UniSR: Vita-Salute San Raffaele University)H-Index: 1
view all 10 authors...
#1Matteo TacelliH-Index: 2
#2Micaela PetroneH-Index: 5
Last. Massimo FalconiH-Index: 79
view all 11 authors...
#1Stefano Partelli (UniSR: Vita-Salute San Raffaele University)H-Index: 29
#2Alessandro ZerbiH-Index: 35
view all 13 authors...
#1Marco Schiavo LenaH-Index: 1
#2Stefano PartelliH-Index: 29
Last. Massimo FalconiH-Index: 79
view all 11 authors...
Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic option for pancreatic neuroendocrine tumors (PanNETs). A possible role for PRRT as a neoadjuvant agent is still largely undetermined, explored only in case reports or small case series. Likewise, the histopathological and immunophenotypic changes induced by PRRT are poorly characterized. In the present study, 24 patients who underwent neoadjuvant PRRT on the basis of their disease's characteristics were retrospectively match...
#1Elettra MerolaH-Index: 6
#2Anja RinkeH-Index: 17
Last. Marianne Pavel (Charité)H-Index: 35
view all 20 authors...
Background While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and...